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Abstract 
CD44, also known as homing cell adhesion molecule is a multi-structural cell molecule involved in cell-cell 
and cell-extracellular matrix communications. CD44 regulates a number of central signaling pathways, 
including PI3K/AKT, Rho GTPases and the Ras-MAPK pathways, but also acts as a growth/arrest sensor, 
and inhibitor of angiogenesis and invasion, in response to signals from the microenvironment. The 
function of CD44 has been very controversial since it acts as both, a suppressor and a promoter of tumor 
growth and progression. To address this discrepancy, we have previously established CD44-inducible 
system both in vitro and in vivo. Next, using microarray analysis, we have identified and validated Survivin, 
Cortactin and TGF-β2 as novel CD44-downstream target genes, and characterized their signaling 
pathways underpinning CD44-promoted breast cancer (BC) cell invasion. This report aims to update the 
literature by adding and discussing the impact of these novel three signaling pathways to better 
understand the CD44-signaling pathways involved in BC tumor cell invasion. 
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Introduction 
Cell adhesion molecules (CAMs) are critical in 
early and late development, and play a major role in 
cellular communication as well as adhesion between 
cells and extracellular matrix [1]. Alteration in the 
expression of CAMs results in loss of cellular 
morphology and tissue architecture, a characteristic 
feature of neoplastic transformation [2, 3]. 
Furthermore, deregulation of CAMs, such as 
E-cadherin results in epithelial-mesenchymal 
transition, thus promoting tumor invasion and 
metastasis [1, 4].  
CD44, a member of the CAM family, along with 
its role in cellular adhesion, is largely involved in 
intracellular signaling for cell growth, proliferation 
and motility [5]. CD44 is involved in the onset of 
several tumors including neuroblastomas, breast, 
ovarian, cervical, prostate, lung and, colon cancers [5]. 
While in neuroblastomas, CD44 acts as a tumor 
suppressor, its role is controversial in prostate (PC) 
and breast cancers (BC) [6, 7]. Interestingly, in BC, 
CD44 expression was associated with poor and 
favorable outcomes, thus indicating the dual nature of 
CD44 in mediating breast tumor development. 
Therefore, in order to address this discrepancy, and 
further elucidate the mechanisms by which CD44 acts 
to either suppress or promote BC invasion, our 
laboratory established a tetracycline inducible 
systems both in vitro and in vivo, and demonstrated 
that induction of CD44 promoted breast tumor cell 
invasion in vitro [8], as well as metastasis of breast 
tumor to the liver [8]. To gain a better understanding 
of the molecular mechanisms associated with CD44s 
downstream signaling in breast tumor progression, 
we performed gene expression profiling analysis and 
validated Survivin (SVV) Cortactin (CTN) and 
TGF-beta2 as novel target genes that underpin 
CD44-promoted invasion of BC cells [8-10]. 









of these three novel signaling pathways (SVV, CTN 
and TGF-β2) to the current mechanisms by which 
CD44 promotes BC progression, and the potential of 
using these novel targets to guide the design of 
anti-BC therapeutic strategies. 
Structure of CD44 
In humans, CD44 proteins are encoded by a 
highly conserved gene, located on the short arm of 
chromosome 11 (11p13), spanning the region 
35,138,869 to 35,232,401. The standard form of CD44 
protein consists of 742 amino acids; The CD44 gene 
encodes for more than 100 isoforms ranging from 80 
to 200 kDa. The heterogeneity of this group is due to 
alternative splicing and protein modification as 
posttranscriptional regulation [8]. 
CD44 encompasses 20 exons spanning a length 
of 60 kb, with the first five exons (Exons 1-5) and the 
last 5 exons (Exons 1-9) being conserved in all the 
isoforms; they encode the N-terminal (extracellular) 
and C-terminal (extracellular, transmembrane and, 
cytoplasmic) domains, respectively for all CD44 
isoforms [11]. The remaining 10 intermediate exons 
(Exons 5a-14; v1-v10) can be involved in alternative 
splicing, thus generating several CD44 variants 
(Figure 1).  
Post-translational modifications with N-glyco-
sylation, O-glycosylation and glycosaminoglycan-
nation by heparan sulphate or chondroitin sulphate 
results in the generation of multiple isoforms (at least 
20 are identified) of variable molecular sizes (85-230 
kDa), suggesting the involvement of CD44 in various 
cellular processes [11, 12].  
The non-variant standard form of CD44, CD44s, 
also known, as hematopoietic CD44 (CD44H) is the 
smallest molecule (85-95kDa), encoded by the 
conserved exons and is the highly expressed CD44 
isoform, and is present on the surface of most 
vertebrate cells [8]. It is a single-chain molecule 
consisting of various domains; distal extracellular 
domain (N-terminal) comprising ligand-binding sites, 
a membrane-proximal region, transmembrane 
domain and, a cytoplasmic domain (Figure 2) [11].  
The variant isoforms of CD44 (CD44v) are 
detected by the presence of variant exons and their 
expression is upregulated by T-lymphocytes and 
other leukocytes post-immunological activation. 
Moreover, these variants have tissue-specific 
expression, regulated by different environment and 
tissue-specific factors, as well as oncogenic pathways, 
particularly the Ras-MAPK pathways that control 
alternative splicing during cancer progression [12, 13] 
While CD44 lacking v2-v10 is the most common form 
on hematopoietic cells; larger CD44 splice variants are 
present on normal and neoplastic epithelia, activated 
lymphocytes and malignant lymphomas [13]. 
CD44v8-10 (CD44E) is frequently dominant on 
epithelial cells, while the longest CD44 isoform, 
CD33v3-10, expressing eight exons of the variable 
region is present in keratinocytes [11].  
Regulation and Signal Transduction 
Mediators of CD44 
Extracellular proteins including hyaluronan 
(HA), collagen, flaminin, fibronectin and osteopontin 
are the known ligands for CD44 [14-18]. Osteopontin 
can bind to the variants, CD44v6 and v7, to initiate 
cell survival, migration, invasion and angiongenesis 
signaling [19]. CD44 is the chief cell receptor for 
hyaluronan (HA), but it is ubiquitous as the gene 
encodes a number of isoforms, generated by 
alternative splicing of 10 "variant" exons. The 
expressions of the variant isoforms are associated 
with different types of cancers, and their expression 
on some cell types can be modulated by particular 
cytokines. CD44 isoforms are heterogeneously 
expressed in breast cancer and correlate with tumor 
subtypes and cancer stem cell markers [20]. 
 
 
Figure 1. Structure of CD44. The exons coding for the various CD44 isoforms are numbered, and the different domains of the protein, including the extracellular, 
the intracellular, and the transmembrane domains are shown. The (Dark blue)-colored exons illustrate the exons that exhibit alternative splicing and their 
rearrangement, resulting in different variant isoforms of CD44. The exons 1-5 correspond to the N-terminal extracellular domain, while the exons 18 and 19 of the 
C-terminal, correspond to the cytoplasmic tail of CD44. 






Figure 2: Structure, binding domains and interactions of CD44. The CD44 protein is composed of an extracellular link domain where the variant isoform is 
located with 292-300 a.a, a stalk-like region in the extracellular module stabilized by disulphide bonding of 6 cysteine residues and contains binding sites for hyalurona 
hyaluronan-binding motifs (HA) as well as facilitate its interactions with matrix metalloproteinases (MMPs) and other growth factors/growth factor receptors. Close 
to The transmembrane region (TM), the variant exon products (Variable region) are inserted. The cytoplasmic tail (CP) and Transmembrane domain undergo both 
phosphorylation on cysteine and serine residues and palmitoylation, respectively with crucial binding motifs for Ankyrin, ErbB2, epidermal growth factor receptor-2; 
ERM/Merlin, ezrin/radixin/moesin; disulphide bonds, PI3K, phosphoinositide 3-kinase, cytoskeletal linker proteins and SRC kinases. 
 
CD44 is responsible for activating a series of key 
signaling pathways, including RhoGTPases, 
Ras-MAPK and, PI3K/AKT pathways. Since CD44 
lacks intrinsic kinase activity, it initiates signaling by 
adapting intracellular kinases and adaptor proteins 
that bind the cytoplasmic tail of CD44 to the actin 
cytoskeletion [21]. CD44 can stimulate signaling by 
interacting with cell-surface associated growth 
factors, enzymes and cytokines [22]. CD44-signal 
transduction occurs through several mechanisms such 
as binding of HA to CD44 resulting in the 
extracellular clustering of CD44, and subsequent 
activation of downstream kinases (Tiam1, p115, Rac1, 
c-Src and FAK as well as Rho and Rac) thereby 
promoting cell migration [23-25]. Bourguinion et al, 
showed that Rho-kinase plays a pivotal role in 
CD44v(3,8-10)-ankyrin interaction and RhoA- 
mediated oncogenic signaling, required for tumor cell 
migration [26]. Furthermore, while CD44 interacts 
with Ezrin/Radixin/Moesin (ERM) proteins to 
facilitate actin cytoskeletal remodeling and cell 
invasion [27], activation of PI3K and inhibition of 
Merlin by Pak2, inhibits CD44 and ERM binding; this 
leads to deregulation of cytoskeletal remodeling and 
promotes cellular invasion [28, 29]. 
Interestingly, CD44 serves as a co-receptor 
physically associated with several other signaling 
receptors [23-25]. Although, in BC cells, CD44 is 
known to interact with EGFR and HER2, our 
understanding of the underlying signaling 
mechanisms is nascent [30, 31]. As matter of fact, 
HA/CD44 can activate Grb2 and p185Her2, resulting 
in the binding of CD44 to N-Wasp, thereby promoting 
Ras- and SOS-mediated growth and invasion [32, 33]. 
Met, receptor for hepatocyte growth factor is 
expressed upon the CD44v6-ERM interaction and 
inhibition of Ras-SOS signaling cascade [34]. 
Furthermore, CD44v6 is known to trigger endothelial 
cell migration via activation of c-Met and VEGFR-2 in 
response to hepatocyte growth factor or VEGF-A; a 
process which requires binding of CD44 to ERM 
proteins [35, 36]. Moreover, CD44 interacts with 
TGFβ-1 and -2 allowing ankyrin-CD44 interaction to 
promote Smad-dependent cell invasion [37]. 
Surprisingly, CD44 can alter angiogenesis by coupling 
to hyaluronidase hyal2 along with transmembrane 
sodium-hydrogen exchanger, NHE1, thereby 
stimulating cathepsin-B to promote invasion, all 
illustrated in (Figure 3) [38, 39]. 





Biological functions of CD44 in cancer 
tissues 
CD44 can regulate various oncogenic signals 
through several key signaling networks, including 
activation of RhoGTPases and PI3K/AKT pathway, 
which augments cytoskeletal remodeling, growth, 
survival and invasion; the hallmarks of tumor 
progression [40]. CD44 couples with major oncogenes 
to enhance their activity and promote tumorigenesis 
and angiogenesis. Furthermore, binding of HA to 
CD44 augments a series of cell signaling events 
through the activation of CD44 C-terminal bound 
proteins such as ankyrin, merlin, and ERM. The CD44 
cytoplasmic tail is directly associated with actin 
filaments in a process mediated by ERM proteins [41]. 
Also, CD44 functions as a docking site for MMPs such 
as MMP-9, allowing degradation of collagen and 
invasion. Docking of MMPs promotes binding of 
TGF-β, thus allowing tumor invasion and 
angiogenesis [42, 43]. HA-mediated motility receptor 
[24] and CD44 interaction is associated with 
metastasis, and RHAMM is over-expressed in several 
tumors including tumors of the ovaries, colon, 
stomach and acute leukemia [44, 45]. 
Although numerous in-vitro studies showed that 
CD44 promotes tumor progression, others 
contradicted its role in tumor progression; its 
interaction with high molecular weight HA represses 
tumor growth, angiogenesis and invasion [5, 46]. In a 
recent study, CD44 interaction with high molecular 
weight HA blocked invasion of several BC cell lines 
[47]. However, another study reported that small 
molecular weight oligomerized HA to initiate 
apoptosis and inhibit PI3K/AKT activation in colon 
cancer cells and murine mammary cancer cells [48].  
CD44 in Breast Cancer 
The role of CD44 in BC progression is 
controversial. CD44 is known to promote BC 
progression and metastasis through the binding of 
CD44 to its major ligand HA, or to other ligands, 
including osteopontin, fibronectin, collagen IV, and 
laminin [49]. Various isoforms of CD44 play a major 
role in the different stages of BC progression and its 
prognosis [47, 50, 51]. Loss of CD44s is linked to 
increased risk of metastasis [50]. Furthermore, loss of 
CD44s expression has been observed in malignant BC 
tissues as compared to benign breast tissues [50]. 
However, our recent in vivo study, contradicted this 
finding, showing that CD44s promoted breast tumor 
invasion and metastasis to the liver [20]. Other studies 
support our findings, indicating that the different 
variants, CD44v3, CD44v6 and, Cd44v7-8 
were positively associated with breast tumor 
progression, poor prognosis, and survival 
rate [52, 53]. Also, the expression of soluble 
CD44v6 was upregulated in tumor tissues 
and was associated with large tumor size 
and lymph node metastasis [54]. In a study 
conducted on invasive cribriform breast 
tumors, while variants CD44v3 and v6 were 
upregulated, the variant, CD44v4 was 
downregulated [55]. However, another 
contradictory study showed that elevated 
expression of CD44v4 promoted BC 
trans-endothelial cell metastasis [56]. In a 
recent study, upregulation of CD44 and 
absence of CD24 in BC stem cells were 
associated with tumorigenesis and poor 
patient survival rate [57-59]. Interestingly, 
with respect to hormone receptors, the 
expression of CD44v6, CD44s and CD44v9 
was positively correlated with breast 
carcinoma tissues displaying high levels of 
estrogen and progesterone receptors [60]. 
Our recent work showed that 
upregulation of CD44s promoted BC 
metastasis to the liver [61]. To gain a better 
understanding of the molecular mechanisms 
associated with CD44s-downstream 
signaling in breast tumor progression, we 
 
 
Figure 3: Representation of the novel signaling pathways that underpin CD44-promoted 
breast tumor cell invasion 





performed microarray gene expression profiling and 
identified Survivin, Cortactin and TGF-β2 as novel 
target genes in underpinning CD44-promoted 
invasion of BC cells [8-10]. The following sections will 
review and discuss the characterization of these novel 
CD44-signaling pathways (SVV, CTN and TGF-β2) 
promoting BC tumor cell invasion. 
Role of Cortactin, Survivin and TGF- 
beta2 in underpinning CD44-promoted 
Breast Cancer Invasion 
Although a number of studies have been 
conducted to understand the upstream signaling 
mechanisms regulating CD44 activity [62], the 
CD44-downstream signaling mechanisms remain 
nascent. Using both in vitro and in vivo CD-44 
inducible BC cell systems, our recent work reported 
that induction of CD44s increased the invasive ability 
of BC cells [8] and their metastasis to the liver [61]. 
Furthermore, we showed that HA activation of CD44 
initiated nuclear localization of NF-κB to bind the 
promoter of CTN, and activate its expression, and 
thus promoting BC progression [13]. However, HA 
binding to CD44 activates the PI3K pathway leading 
to the release of E2F1, which translocate to the nucleus 
to activate the transcription of SVV.  
Cortactin (CTN) 
We have previously identified EMS/cortactin as 
a transcriptional target of HA/CD44 signaling [8-10], 
a gene whose expression is upregulated in at least 
15% of BCs and is associated with poor prognosis and 
relapse; majorly being linked with gene amplification 
of chromosome 11q13 [63]. CTN plays a role in the 
polymerization of the actin cytoskeleton; thus 
allowing cells to lose their adherence capability and 
become motile [8], a feature allowing the cancer cells 
in-vitro to adhere to bone-marrow endothelial cells 
and trigger metastasis to the bone in-vivo [35]. In 
invasive BC cells, CTN forms a complex with paxillin 
and PKCµ, thus regulating cell motility and adhesion. 
Furthermore, overexpression of CTN in BC cells, 
restricts the ubiquitination-mediated breakdown of 
the epidermal growth factor receptor [64], leading to a 
prolonged ligand-initiated EGFR activity [65, 66]. 
CTN has been described to be a signaling target of 
CD44-activated p60 Src kinase [62]. CTN has been 
identified to regulate E-selectin and ICAM-1 activity 
to allow adherence of leukocytes to endothelial cells at 
sites of inflammation [67]. 
Our previous studies revealed the molecular 
mechanisms that underpin CD44-promoted BC 
metastasis and identified NF-κB as the main 
transcription factor involved in CTN regulation [8]. 
Upon pharmacological inhibition of NF-κB in 
MCF7-B5 cells using IκKinase-2 inhibitor SC514 or 
RNAi-mediated inhibition of p65 Rel A expression, 
induced HA/CD44 induced followed by increased 
CTN levels [8]. Furthermore, we identified two other 
critical transcriptional CD44 downstream-target 
genes, survivin (SVV) and transforming growth 
factor-β2 (TGF- β2) that mediate breast tumor 
invasion and metastasis [8, 9, 61]. 
Survivin (SVV) 
SVV plays a pivotal role as an anti-apoptotic 
factor, cell survival and resistance to chemotherapy. 
SVV has three distinctive features, making it distinct 
from other anti-apoptotic proteins: (i) Although, SVV 
is moderately expressed in normal human tissues, it is 
however overexpressed in human tumors, (ii) SVV 
inhibits the pro-apoptotic functions of caspases, due 
to its baculovirus apoptosis-inhibitor repeat domain, 
and [68] SVV is merely the only anti-apoptosis protein 
firmly regulated throughout the process of cell cycle 
[61]. SVV has a dual role as its serves as an 
anti-apoptotic and a promoter of cell survival and 
proliferation, thus, making it a potential molecular 
target for BC therapy [69]. 
In a murine BC model, mice treated with a 
plasmid (construct of mouse SVV phosphorylation 
T34A mutant) inhibited metastasis of BC to the lung 
[70]. Furthermore, siRNA-inhibition of SVV 
significantly reduced colorectal cancer cell 
proliferation and abolished resistance to radiotherapy 
[71]. A dominant-negative form of SVV inhibited both 
BC cell proliferation and angiogenesis [72]. Despite 
significant number of studies from the literature 
exploring SVV function, its role in the onset and the 
progression of BC, as well as its underlying 
mechanisms are still nascent. In fact, we have 
identified a novel relationship between CD44/HA 
signaling and the transcription of SVV in BC cells 
using microarray analysis [9]. Specific siRNA 
inhibition of induced or endogenous CD44 expression 
reduced SVV expression, which was functionally 
accompanied by a decrease in BC cell invasiveness [9]. 
Furthermore, we revealed that HA/CD44/PI3K/ 
activating the transcription of SVV is the underlying 
molecular signaling mechanism [9]. Activation of 
E2F1 increased SVV expression, possibly via direct 
interaction with the SVV promoter, leading to breast 
tumor cell invasion [9]. Nevertheless, further work is 
required to determine the molecular link between 
SVV and induction of breast tumor invasion.  
More interestingly, we have identified and 
validated an additional protein, transforming growth 
factor β2 (TGF-β2), (2.9 fold induction) as a novel 





potential CD44s-target involved in breast tumor cell 
invasion [10]. 
Transforming Growth Factor-β2 (TGF-β2) 
TGF-β2 is a part of the large family of 
polypeptide growth factors, involved in the 
regulation of various biological processes such as 
cellular growth, proliferation, angiogenesis, immune 
response, cell death, extracellular matrix synthesis 
and differentiation [73]. TGF has three isoforms that 
are generally secreted as precursor molecules, all 
being triggered either by protolytic cleavage, pH 
change or interaction with integrins [74]. The active 
form of TGF tends to bind to certain receptors, 
transmembrane serine/threonine kinases, all being 
known to activate the SMAD signaling cascade [74].  
Several studies showed that TGF-β2 is involved 
in the onset and progression of several tumors, 
including ovarian [75] and pancreatic [76] cancer, 
melanoma [77] and malignant epidermal 
keratinocytes [78]. TGF-β2 activation is a crucial step 
in the CD44-downstream event during tumor cell 
survival and proliferation [37]. Furthermore, 
polymorphism in TGF-β2 promoter increased its 
protein expression levels, which was associated with 
lymph node metastasis in BC patients, thus providing 
evidence of the role of TGF-β2 in the process of breast 
tumor invasion [79]. Epithelial-mesenchymal 
transition (EMT) was associated with cancer invasion 
and metastasis, and TGF-β signaling cascade is 
known to regulate EMT in the breast [80, 81]. Recent 
study showed that HA/CD44-moesin complex, 
linked with TGF-β2 receptor II and clathrin at actin 
microdomains, promotes activation of TGF-β 
signaling; this results in actin remodeling, thus 
causing cell-cell detachments and increased cell 
motility [80]. 
Our study provided evidence that TGF-β2 is a 
downstream transcriptional target of CD44-mediated 
BC invasion, which could stimulate TGF-β2 
transcription through the activation of the 
transcription factor, cAMP response element-binding 
protein (CREB) [10]. Data from several previous 
studies support our findings. In fact, CD44 undergoes 
a series of chronological metalloprotease and 
ϒ-mediated proteolytic cleavage, resulting in the 
release and translocation of CD44 intracellular 
domain (CD44-ICD) to the nucleus; CD44-ICD can 
bind CREB, increases phosphorylation of S133 and 
triggers CREB-mediated gene transcription, leading to 
activation of TGF-β2 [21, 82, 83]. Interestingly, , cAMP 
response element/activating transcription factor 
(CREB/ATF) and E-motif were found within the 
TGF-β2 gene promoter just upstream the transcription 
start site, and were necessary for the TGF-β2 gene 
transcription [83]. Experiments are being carried out 
in our laboratory to further validate the in-vivo 
functional role of CD44/CREB/ TGF- β2 signaling 
pathway in breast tumor progression and metastasis.  
CD44 in other cancers 
The promoter region of CD44 consists of a CpG 
island, which when undergoes hypermethylation at 
the CpG dinucleotides will suppress transcription of 
CD44s in prostate cancer (PCa) [84]. Furthermore, loss 
of CD44s expression is used to predict PCa recurrence 
in surgically treated patients [85]. As mentioned 
above, Rho plays a critical role in promoting CD44 
expression; Elevated levels of Rho GTPases by certain 
CD44 variants tend to upregulate CD44/MMP-9 
interaction, MMP-9 secretion and cell motility, a 
crucial step in PCa progression [86, 87]. The variants, 
CD44v6 and CD44v7-10 have been positively linked 
with PCa [88].  
In colon cancer, elevated expression of CD44v6 
and CD44v8-10 is reported to promote HA binding, 
tumorigenicity and distant metastasis. Furthermore, 
variant, CD44v3 along with heparanase is also linked 
with colon cancer metastasis [89, 90]. Upregulated 
expression of CD44 with its variant CD44v6 has been 
positively correlated with colon cancer progression 
and spread, and is also a marker for poor prognosis 
and survival [91, 92]. Several CD44v isoforms are 
overexpressed in malignant colon cancer cells; 
CD44v3, v5, v6 and v8-10 have been suggested to be 
possible prognostic indicators in colon cancer [91, 
93-95]. 
On the other hand, expressions of CD44 
isoforms, including single-variants (Exons v3, v4, v6 
or v9) were downregulated in brain cancers [96]. 
Interestingly, multiple CD44 variants were 
upregulated in metastatic brain tumors, while these 
isoforms were absent in cells metastasizing to the 
spine [97]. In a separate study, CD44s, CD44v3, 
CD44v4, CD44v6, and CD44v7 expression was 
reduced in pancreatic cancer cells as compared to 
normal cells [98]. Interestingly, expression of the 
variant CD44v2 was expressed in pancreatic tumor 
cells, and was correlated with vessel invasion [99].  
In another study, CD44 isoforms (Cd44s, v5, v6, 
v7-8 and v10) were highly expressed in poorly 
differentiated hepatocellular carcinoma and 
correlated with poor survival rate [100]. Furthermore, 
CD44v6 was linked to vascular invasion [100].  
In non-squamous cell lung carcinoma, 
upregulated expression of CD44v6 was associated 
with metastasis and poor prognosis; however, in 
adenocarcinoma and large cell lung carcinoma, loss of 
CD44v6 and CD44v3 were associated with poor 





prognosis and correlated with invasion of lung 
adenocarcinoma [101, 102].  
In stages II and III of rectal cancer, CD44v6 was 
associated with predicting recurrence of locally 
advanced adenocarcinoma [103]. Also, CD44v6 and 
v7-8 have been identified as predictors of cervical 
cancer at earlier stage [104]. In Non-Hodgkin 
Lymphoma, variants, CD44v6-10 were highly 
expressed. Studies using in-vivo models reported that 
CD44ex10 was positively correlated with the onset of 
tumor and metastasis as compared to the larger exon 
10 variants (CD44ex10-14 and CD44ex7-14) and 
CD44H [105]. 
Conclusion 
CD44 is a multifaceted molecule involved in 
several biological and pathological processes. CD44 
plays a crucial role in the process of metastasis, 
including EMT, cellular growth, proliferation, 
invasion and motility. Its role in metastasis was first 
identified in pancreatic cancer [64]. Several studies 
have suggested its role in different stages of tumor 
progression. CD44 can act as both, tumor promoter 
and tumor suppressor depending on cancer cell type.  
Since its role was controversial in cancer, our 
laboratory has extensively investigated its role in BC 
using Tet-Off inducible system combined with 
microarray analysis and various molecular and 
functional approaches, in order to better understand 
its precise function in metastasis and further 
determine the specific underlying mechanisms. We 
have indeed discovered and functionally validated 
three disctinct novel signaling pathways, HA- 
CD44/PI3K/E2F1/SVV, HA-CD44/ NF-κB/CTN, 
and HA-CD44/CREB/TGF-β2 as novel 
CD44-downtream signaling pathways underpinning 
CD44-promoted breast tumor cell invasion (Fig. 2). 
One of the major elements required for 
improving the longevity and quality of a patient’s life 
is the development of early detection methods and 
targeted therapies that can aid in controlling cancer 
metastasis. Although, CD44 is not a stable marker for 
luminal BC subtypes, it frequently serves as a marker 
for triple-negative BC [106, 107]. Our long-term 
objective is to gain a comprehensive understanding of 
the molecular mechanisms of CD44-mediated BC 
progression and metastasis, in order to identify 
molecular candidates that can serve as biomarkers 
and /or targets to pave the way towards the design of 
efficient anti-metastasis therapeutic strategies. 
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